Horizon Discovery Group plc: Capital Markets Day Date Change to 5 March 2018
February 20 2018 - 6:02AM
Horizon Discovery Group plc
Capital Markets Day Date Change to 5 March
2018
Cambridge, UK, 20 February 2018: Horizon
Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global
leader in gene editing and gene modulation technologies, announces
that as a result of the leadership changes announced separately
today, the Capital Markets Day in London for investors and
sell-side analysts, will now take place on 5 March 2018 at Etc.
Venues Fenchurch Street, 43/44 Crutched Friars, London, EC3N 2HH
starting at 13:00 GMT / 8:00 EDT.
There will be a simultaneous live conference call and webcast
for those unable to attend in person. The webcast, with the
presentation slides, will be available at
https://www.horizondiscovery.com/about-us/investor-relations and a
recording will be made available shortly thereafter.
Please contact horizon@consilium-comms.com if
you would like to attend.
ENDS
For further information from Horizon Discovery Group plc,
please contact:
Horizon Discovery Group plcIan Gilham,
Chairman Richard Vellacott, Interim Chief Executive OfficerTel: +44
(0) 1223 655 580
Numis Securities Limited (Broker and
NOMAD)Michael Meade / Freddie Barnfield Tel: +44 (0) 207 260
1000
Consilium Strategic Communications (Financial
Media and Investor Relations)Mary-Jane Elliott / Matthew Neal /
Melissa GardinerTel: +44 (0) 20 3709 5701Email:
horizon@consilium-comms.com
About Horizon Discovery Group plc
www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD)
("Horizon") is a world leader in gene editing and gene modulation
technologies. Horizon designs and engineers cells using its
translational genomics platform, a highly precise and flexible
suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and,
following the acquisition of Dharmacon, Inc., its functional
genomics platform comprising gene knockdown (RNAi) and gene
expression (cDNA, ORF) tools, for research and clinical
applications that advance human health. Horizon's platforms and
capabilities enable researchers to alter almost any gene or
modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue
products and related research services to support a greater
understanding of the function of genes across all species and
the genetic drivers of human disease and the
development of personalised molecular, cell and gene therapies.
These have been adopted by over 10,000 academic, drug
discovery, drug manufacturing and clinical diagnostics customers
around the globe, as well as in the Company's own R&D
pipeline.
Horizon is headquartered in Cambridge, UK, and
is listed on the London Stock Exchange's AIM market under the
tic
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024